BAYER AG NA
Commented by Armin Schulz on November 20th, 2024 | 07:00 CET
Evotec, Nyxoah, Bayer – A lot of excitement in the healthcare industry
The healthcare sector is currently abuzz with activity. Evotec is the focus of a potential takeover by the US company Halozyme, which has caused the shares of the German biotech company to skyrocket. At the same time, the Belgian medical technology company Nyxoah expects to receive FDA approval soon for its Genio system for the treatment of sleep apnea, which would pave the way for its market entry in the US. Bayer, on the other hand, disappointed with its latest quarterly figures, which showed a significant decline in revenue and EBITDA, leading to a slide in its share price. We take a closer look at these three companies.
Read
Commented by André Will-Laudien on November 13th, 2024 | 07:30 CET
Gold correction - Now is the time to take advantage of the lows! Takeover rumors at Evotec, Desert Gold, Bayer and SMCI
The re-election of Donald Trump as US President had varying effects on the capital markets. The US dollar gained against all currencies, while the hot topic Bitcoin reached new all-time highs of over USD 90,000. The enormous influx of funds into the US stock markets initially slowed down other exchanges. At the same time, the previously sought-after precious metals corrected sharply, putting pressure on mining stocks again. The first shockwaves have now been absorbed, and attention is turning to the real political issues that the White House will now push forward. Defense, industry, and security are in the spotlight, while biotech and green tech remain sidelined. There are some interesting special movements that we will examine here.
Read
Commented by Armin Schulz on November 12th, 2024 | 07:00 CET
Bayer, BioNxt Solutions, Novo Nordisk – Opportunities in the healthcare industry
In a market characterized by technological breakthroughs and the growing demand for innovative therapies, companies such as Bayer, BioNxt Solutions and Novo Nordisk offer exciting investment opportunities. While Bayer, a global pharmaceutical giant with a broad product portfolio, promises stability and long-term growth, BioNxt Solutions relies on highly specialized biotechnological innovations with disruptive potential. Novo Nordisk, a leading player in diabetes and metabolic disorders, is benefiting from the growing demand for solutions for chronic diseases. For investors looking to capitalize on trends in the healthcare industry, these three companies could make all the difference.
Read
Commented by André Will-Laudien on November 6th, 2024 | 08:00 CET
US election and the biotech sector – A hot November is on the cards! BioNTech, Pfizer, Nyxoah, Bayer or Evotec?
With anticipation building for both the Q3 earnings season and the US election results, the markets are in a wait-and-see mode. Democrat frontrunner Kamala Harris is said to be committed to continuing the successful policies of her predecessor Joe Biden. Of course, science, research and climate protection are in the spotlight. Her rival, Donald Trump, is said to be more concerned with strengthening the traditional economy, where automotive engineering, the defense industry and security companies come to the fore. Additionally, markets are looking to central banks for cues, as lower interest rates would be a boon for the biotech sector. Here are some investment ideas for dynamic investors in this promising climate.
Read
Commented by André Will-Laudien on October 24th, 2024 | 07:30 CEST
Biotech – Are takeovers looming amidst curious prices? Evotec, Bayer, Vidac Pharma and BioNTech in the spotlight
The biotech sector is once again in the spotlight. Since the acquisition of MorphoSys at the beginning of the year, the speculation carousel is turning again. Is Evotec next, or maybe Vidac Pharma? The Hamburg-based drug specialist came under fire from short-sellers after the resignation of long-standing CEO Lanthaler, who had shorted over 4% of the capital by mid-September. However, the price stubbornly held above the EUR 5 mark, and yesterday saw a 10% rise to EUR 6.60. What is behind this? Last week, it was Vidac Pharma that surged 300% from a standing start with enormous trading volumes. The thought processes of market participants are evident: interest rates are falling, making refinancing attractive again for upcoming financial investors. We shed light on the key players.
Read
Commented by Fabian Lorenz on October 23rd, 2024 | 07:30 CEST
More than 100% upside potential! Bayer, Plug Power and 123fahrschule – Which stock is convincing?
Analysts see more than a 100% upside potential in the 123fahrschule stock. The exciting second-line stock wants to make driver education more modern and efficient and is getting support from politicians. Accordingly, sales and profits should rise sharply. Plug Power can also show rising sales, but like industry colleague Nel, the Americans are unable to get a grip on their losses. Will the quarterly figures turn things around? Bayer shareholders have been waiting for a turnaround for quite some time. But analysts also expect falling profits in the coming quarterly report. Is there still potential for a 40% increase in the DAX share?
Read
Commented by Armin Schulz on October 15th, 2024 | 07:15 CEST
Volkswagen and Bayer with problems – 123fahrschule, on the other hand, with great growth potential
As the German economy undergoes a profound transformation, traditional industries are facing significant challenges. Giants like Volkswagen and Bayer are experiencing difficult times with shrinking margins and structural changes. Volkswagen, Europe's leading automaker, is struggling with falling profits in its core brand despite high group earnings and is planning rigorous cost-cutting measures that could jeopardize jobs. Similarly, Bayer is being forced to make extensive job cuts and reorganize. However, in the midst of these crises, new opportunities are also emerging: companies like 123fahrschule are using innovative strategies to thrive in the education sector. Today, we take a closer look at these three companies.
Read
Commented by Stefan Feulner on October 14th, 2024 | 07:00 CEST
Bayer, Vidac Pharma, Evotec – Enormous potential
Since the US Federal Reserve cut key interest rates and signaled a continuation of its loose monetary policy, the Nasdaq Biotech Index has been on an upward trajectory and has significantly outperformed the broader market in recent days. The correction of the past few months seems to be over in this sector, and the all-time high from August 2021 is within reach. In addition to rising share prices, the number of acquisitions is also increasing significantly, a sign of the undervaluation of many listed companies.
Read
Commented by Fabian Lorenz on October 9th, 2024 | 07:15 CEST
Biotech comeback and takeover fantasy! BioNTech, Bayer, and Vidac Pharma
Money can be made in biotech shares again! However, investors need to look carefully. While Moderna is at a multi-year low, BioNTech and Vidac Pharma have gained over 50% in just a few months. Is there more to come? The chances are good, as both biotech companies have released promising news. Analysts see a tenfold increase in the case of Vidac Pharma, and the focus on the fight against cancer makes the Company a takeover candidate. The cancer specialist would also be a good fit for Bayer and BioNTech, and the share is still cheap. BioNTech is becoming an investment darling again and is focusing on AI. Bayer has yet to make the leap above EUR 30, and analysts are warning about the upcoming quarterly figures.
Read
Commented by Fabian Lorenz on October 3rd, 2024 | 14:05 CEST
100% with HelloFresh! Are Bayer and dynaCERT taking off next?
Since the low in June, the HelloFresh share has roughly doubled. Not bad for an MDAX-listed stock with a market capitalization of EUR 1.6 billion. Can it continue at this pace, or would it be better to take profits? Analysts weigh in with their assessment. dynaCERT shows great potential. With a new German CEO, the Canadian company aims to make diesel engines more efficient and low-emission in Europe. And what is Bayer doing? Will the positive news flow help it to break out of the consolidation?
Read